Chronic-cough due to bronchiectasis: ACCP evidence-based clinical practice guidelines

Chest

Volumn 129, Issue 1 SUPPL., 2006, Pages 122S-131S

  Rosen, Mark J ^a  

^a BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

Allergic bronchopulmonary aspergillosis; Antibiotics; Bronchiectasis; Bronchodilators; Chest physiotherapy; Cystic fibrosis; Mucolytics; Mycobacterium avium complex; Primary ciliary dyskinesia

Indexed keywords

ANTIBIOTIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; DORNASE ALFA; IBUPROFEN; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MUCOLYTIC AGENT; TOBRAMYCIN;

BREATHING EXERCISE; BRONCHIECTASIS; BRONCHOPULMONARY ASPERGILLOMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CILIARY DYSKINESIA; CLINICAL TRIAL; COCHRANE LIBRARY; COMMON VARIABLE IMMUNODEFICIENCY; COUGHING; CYSTIC FIBROSIS; DISEASE EXACERBATION; DISEASE PREDISPOSITION; EVIDENCE BASED MEDICINE; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNITY; LUNG TRANSPLANTATION; MEDLINE; MUCOCILIARY CLEARANCE; MYCOBACTERIUM INTRACELLULARE AVIUM; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECURRENT INFECTION; RESPIRATORY TRACT INFECTION; REVIEW; SPIROMETRY; SPUTUM;

EID: 33144466528     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.129.1_suppl.122S     Document Type: Article

References (66)

1. Reid L. Reduction in bronchial subdivision in bronchiectasis. Thorax 1950; 5:233-247
2. Barker A. Bronchiectasis. N Engl J Med 2002; 346:1383-1393
3. Singleton R, Morris A, Redding G, et al. Bronchiectasis in Alaska Native children: causes and clinical courses. Pediatr Pulmonol 2000; 29:182-187
4. Smith I, Jurriaans E, Diederich S, et al. Chronic sputum production: correlations between clinical features and findings on high resolution computed tomographic scanning of the chest. Thorax 1996; 51:914-918
5. Gaga M, Bentley A, Humbert M, et al. Increases in CD4+ T lymphocytes, macrophages, neutrophils, and interleukin 8 positive cells in the airways of patients with bronchiectasis. Thorax 1998; 53:685-691
6. Tsang K, Chan K, Ho P, et al. Sputum elastase in steady-state bronchiectasis. Chest 1998; 117:420-426
7. Sepper R, Konttinen Y, Ding Y, et al. Human neutrophil collagenase (MMP-8), identified in bronchiectasis BAL fluid, correlates with severity of disease. Chest 1995; 107:1641-1647
8. Shum D, Chan S, Ip M. Neutrophil-mediated degradation of lung proteoglycans: stimulation by tumor necrosis factor-alpha in sputum of patients with bronchiectasis. Am J Respir Crit Care Med 2000; 162:1925-1931
9. Liebow A, Hales M, Lindskog G. Enlargement of the bronchial arteries and their anastamoses with the pulmonary arteries in bronchiectasis. Am J Pathol 1949; 25:211-231
10. Reiff D, Wells A, Carr D, et al. CT findings in bronchiectasis; limited value in distinguishing between idiopathic and specific types. AJR Am J Roentgenol 1995; 165:261-267
11. Irwin R, Curley F, French C. Chronic cough: the spectrum and frequency of causes, key components of diagnostic evaluation and outcomes of specific therapy. Am Rev Respir Dis 1990; 141:640-647
12. Smyrnios N, Irwin R, Curley F. Chronic cough with a history of excessive sputum production: the spectrum and frequency of causes and key components of the diagnostic evaluation, and outcome of specific therapy. Chest 1995; 108:991-997
13. Brightling C, Ward R, Goh K, et al. Eosinophilic bronchitis is an important cause of cough. Am J Respir Crit Care Med 1999; 160:406-410
14. Schaefer O, Irwin R. Unsuspected bacterial suppurative disease of the airways presenting as chronic cough. Am J Med 2003; 114:602-606
15. Dinwiddie R. Pathogenesis of lung disease in cystic fibrosis. Respiration 2000; 67:3-8
16. Wilson C, Jones PW, O'Leary CJ, et al. Effect of sputum bacteriology on the quality of life of patients with bronchiectasis. Eur Respir J 1997; 10:1754-1760
17. McGuinness G, Naidich D. CT of airways disease and bronchiectasis. Radiol Clin North Am 2002; 40:1-19
18. Grenier P, Maurice F, Musset D, et al. Bronchiectasis: assessment by thin-section CT. Radiology 1986; 161:95-99
19. Ouellette H. The signet ring sign. Radiology 1999; 212:67-68
20. Desai S, Wells A, Rubens M, et al. Traction bronchiectasis in cryptogenic fibrosing alveolitis: associated computed tomographic features and physiological significance. Eur Radiol 2003; 13:1801-1808
21. Pasteur M, Helliwell S, Houghton J, et al. An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med 2000; 162:1277-1284
22. Boucher R. New concepts in the pathogenesis of cystic fibrosis lung disease. Eur Respir J 2004; 23:146-158
23. Stern R. Current concepts: the diagnosis of cystic fibrosis. N Engl J Med 1997; 336:487-491
24. DeGraci J, Rodrigo J, Morell F, et al. IgG subclass deficiencies associated with bronchiectasis. Am J Respir Crit Care Med 1996; 153:650-655
25. Busser P, Razvi S, Cunningham-Rundles C. Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency. J Allergy Clin Immunol 2002; 109:1001-1004
26. Sacher R, Panel IA. Intravenous immunoglobulin consensus statement. J Allergy Clin Immunol 2001; 108:8139-8146
27. Holmes A, Trotman-Dickenson B, Edwards A, et al. Bronchiectasis in HIV disease. J Med 1992; 85:307-308
28. Verghese A, Al-Samman M, Nabhan D, et al. Bacterial bronchitis and bronchiectasis in human immunodeficiency virus infection. Arch Intern Med 1994; 154:2086-2091
29. Noone P, Leigh M, Sannuti A, et al. Primary ciliary dyskinesia: diagnostic and phenotypic features. Am J Respir Crit Care Med 2004; 169:459-467
30. Bush A, Cole P, Hariri M, et al. Primary ciliary dyskinesia: diagnosis and standards of care. Eur Respir J 1998; 12:982-988
31. Soubani A, Chandrasekar P. The clinical spectrum of pulmonary aspergillosis. Chest 2002; 121:1988-1999
32. Ricketti A, Greenberger P, Mintzer R, et al. Allergic bronchopulmonary aspergillosis. Chest 1984; 86:773-778
33. Greenberger P. Allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol 2002; 110:685-692
34. Patterson R, Greenberger P, Halwig J, et al. Allergic bronchopulmonary aspergillosis: natural history and classification of early disease by serologic and roentgenographic studies. Arch Intern Med 1986; 146:916-918
35. Stevens D, Lee J, Schwartz H, et al. A randomised trial of itraconazole in allergic bronchopulmonary aspergillosis. N Engl J Med 2000; 342:756-762
36. Wark P, Hensley M, Saltos N, et al. Anti-inflammatory effect of itraconazole in stable allergic bronchopulmonary aspergillosis: a randomized controlled trial. J Allergy Clin Immunol 2003; 111:952-957
37. Elphick H, Southern K. Antifungal therapies for allergic bronchopulmonary aspergillosis in people with cystic fibrosis. Cochrane Database Syst Rev (database online). Issue 2, 2004
38. Prince D, Peterson D, Steiner R, et al. Infection with Mycobacterium avium complex in patients without predisposing conditions. N Engl J Med 1989; 321:863-868
39. Reich J, Johnson R. Mycobacteriun avium complex pulmonary disease presenting as an isolated lingular or middle lobe pattern: the Lady Windermere syndrome. Chest 1992; 101:1605-1609
40. Wallace R, Glassroth J, Griffith D, et al. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am J Respir Crit Care Med 1997; 156:S1-S25
41. Huang J, Kao P, Adi V, et al. Mycobacterium avium-intracellulare pulmonary infection in HIV-negative patients without preexisting lung disease: diagnostic and management limitations. Chest 115:1033-1040, 1999
42. Cortet B, Periez T, Roux N, et al. Pulmonary function tests and high resolution computed tomography of the lungs in patients with rheumatoid arthritis. Ann Rheum Dis 1997; 56:596-600
43. Camus P, Piard F, Ashcroft T, et al. The lung in inflammatory bowel disease. Medicine (Baltimore) 1993; 72:151-183
44. Cohen M, Sahn S. Bronchiectasis in systemic disease. Chest 1999; 116:1063-1074
45. Franco F, Sheikh A, Greenstone M. Short acting β-2 agonists for bronchiectasis. Cochrane Database Syst Rev (database online). Issue 2, 2004
46. Sheikh A, Nolan D, Greenstone M. Long-acting β-2-agonists for bronchiectasis. Cochrane Database Syst Rev (database online). Issue 2, 2004
47. Corless J, Warburton C. Leukotriene receptor antagonists for non-cystic fibrosis bronchiectasis. Cochrane Database Syst Rev (database online). Issue 2, 2004
48. Steele K, Lasserson J, Greenstone M. Oral methyl-xanthines for bronchiectasis. Cochrane Database Syst Rev (database online). Issue 2, 2004
49. Crocket A, Cranston J, Latimer K, et al. Mucolytics for bronchiectasis. Cochrane Database Syst Rev (database online). Issue 2, 2004
50. Wills P, Wodehouse T, Corkery K, et al. Short-term recombinant human DNase in bronchiectasis: effect on clinical state and in vitro sputum transportability. Am J Respir Crit Care Med 1996; 14:413-417
51. O'Donnell A, Barker A, Ilowite J, et al. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase. Chest 1998; 113:1329-1334
52. Jones A, Wallis CE, Kearney CE. Recombinant human deoxyribonuclease for cystic fibrosis. Cochrane Database Syst Rev (database online). Issue 2, 2004
53. Elborn J, Johnston B, Allen F, et al. Inhaled steroids in patients with bronchiectasis. Respir Med 1992; 86:121-124
54. Tsang KW, Ho PL, Lam WK, et al. Inhaled fluticasone reduces sputum inflammatory indices in severe bronchiectasis. Am J Respir Crit Care Med. 1998; 158:723-727
55. Lasserson J, Holt K, Greenstone M. Oral steroids for bronchiectasis (stable and acute exacerbations). Cochrane Database Syst Rev (database online). Issue 2, 2004
56. Cheng K, Ashby D, Smyth R. Oral steroids for cystic fibrosis. Cochrane Database Syst Rev (database online). Issue 2, 2004
57. Auerbach H, Williams M, Kirkpatrick J, et al. Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet 1985; 2:686-688
58. Eigen H, Rosenstein BJ, FitzSimmons S, et al. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. J Pediatr 1995; 126:515-523
59. Greally P, Jussain P, Vergani D, et al. Interleukin-1 α, soluble interleukin-2 receptor, and IgG concentrations in cystic fibrosis treated with prednisolone. Arch Dis Child 1994; 71:35-39
60. Dezateux C, Crighton A. Oral non-steroidal anti-inflammatory drug therapy for cystic fibrosis. Cochrane Database Syst Rev (database online). Issue 2, 2004.
61. Evans D, Bara A, Greenstone M. Prolonged antibiotics for purulent bronchiectasis. Cochrane Database Syst Rev (database online). Issue 2, 2004
62. Ramsey B, Pepe M, Quan J, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999; 340:23-30
63. Barker A, Couch L, Fiel SB, et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med 2000; 162:481-485
64. Agasthian T, Deschamps C, Trasek V, et al. Surgical management of bronchiectasis. Ann Thorac Surg 1996; 62:990-993
65. Balkanli K, Dakak G, Gurkok S, et al. Surgical management of bronchiectasis: analysis and short-term results in 238 patients. Eur J Cardiothorac Surg 2003; 24:699-702
66. Irwin R, Boulet L-P, Cloutier M, et al. Managing cough as a defense mechanism and as a symptom: a consensus panel report of the American College of Chest Physicians. Chest 1998; 114:1335-1815